Drug Trial Radar · NCT07304154
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
57
Planned (sponsor's estimate)
Start
Apr 10, 2026
Primary completion
Dec 2031
Study completion Dec 2031
Sponsor
- Lead sponsor
- Kite, A Gilead CompanyGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Dec 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases. The primary objectives of this study are: * To evaluate the safety and tolerability of KITE-363 in participants with autoimmune neurologic diseases * To determine the recommended dose for Phase 1b * To evaluate the safety and preliminary efficacy of KITE-363 in participants with autoimmune neurologic diseases
Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Myasthenia Gravis
- Multiple Sclerosis
Interventions
KITE-363Biological
A single infusion of CAR-transduced autologous T cells administered as intravenous infusion.
FludarabineDrug
Administered intravenously
CyclophosphamideDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a: Percentage of Participants Experiencing Treatment-emergent Adverse Event (TEAEs)Time frame: Up to 3 years
- Phase 1a: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) After the Infusion of KITE-363Time frame: Up to 28 days
- Phase 1b: (All Cohorts) Percentage of Participants Experiencing TEAEsTime frame: Up to 3 years
- Phase 1b: Relapsing Forms of MS (RRMS) and Active Secondary-progressive Multiple Sclerosis (aSPMS): Number of New T1 Gadolinium Enhancing (GadE+) Lesions on Magnetic Resonance Imaging (MRI) at Week 12Time frame: Week 12
- Phase 1b: Relapsing Forms of MS (RRMS and aSPMS): Number of New and/or Enlarging T2 Lesions on MRI at Week 12Time frame: Week 12
- Phase 1b: Progressive Forms of MS (PPMS) and Non-active Secondary-progressive Multiple Sclerosis (naSPMS): Time to Onset of Confirmed Disability Progression Over 12 Weeks (CDP-12)Time frame: Up to 3 years
- Phase 1b: Myasthenia Gravis (MG): Proportion of Participants of MG Activities of Daily Living (MG-ADL) RespondersTime frame: Up to 3 years
- Phase 1b: CIDP: Proportion of Participants with a ≥ 2 Points Improvement from Baseline in aINCAT Score at Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory TherapyTime frame: Up to 3 years
Locations
10 sites in 3 countries. Site status is shown where the registry gives one.
Hoag Memorial Hospital Presbyterian
Newport Beach, California · Recruiting
Stanford Neuroscience Health Center
Palo Alto, California · Recruiting
Columbia University Irving Medical Center
New York, New York · Recruiting
LDS Hospital - Intermountain Health
Salt Lake City, Utah · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Concord Repatriation General Hospital
Sydney, New South Wales, Australia · Recruiting
Corner Hawkesbury Road and Darcy Road
Westmead, New South Wales, Australia · Recruiting
Centre Intégré Universitaire de Sante et Services Sociaux de L'Est de I'lle de Montreal / installation Hopital Maisonneuve-Rosemont
Montreal, Canada · Recruiting
Jewish General Hospital
Montreal, Canada · Recruiting
The Ottawa Hospital - General Campus
Ottawa, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.